Acquisition Opportunity Diablo Clinical Research was acquired by Flourishresearch in February 2025, presenting a potential cross-sell or integration opportunity for Flourish’s cardiovascular, metabolic, neuroscience, and infectious disease trial capabilities to expand service offerings for existing clients or consolidate site networks.

Scale and Reach With a patient database of over 12,000 and a track record of over 600 studies, the company demonstrates substantial research capacity and enrollment potential that can be leveraged for faster study startup timelines and improved participant recruitment for sponsor programs.

Therapeutic Expertise Hospitals and investigators specialize in endocrinology, internal medicine, cardiology, and neurology, indicating strong domain depth that aligns with sponsors pursuing multi-therapeutic Phase I–IV trials and medical device studies.

Mid-Sized Advantage As a smaller research organization with 11–50 employees, Diablo Clinical Research can offer personalized site management, flexibility, and rapid decision-making while integrating into larger sponsor networks seeking diverse, multi-site participation.

Online and Analytics Readiness Current tech stack includes MySQL, Microsoft 365, Google Analytics, and WordPress; these capabilities can be leveraged to demonstrate robust data handling, patient engagement, and transparent trial dashboards to potential sponsors.